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FIGURE 1 Platelet Inhibition Over Time
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Platelet reactivity was assessed at baseline, 1, 2, 4, and 8 h after a 180-mg ticagrelor loading dose in patients treated by crushed tablets
(diamonds) or integral tablets (squares). Data are expressed as mean  SD.
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512enhanced drug absorption, a pharmacokinetic
analysis could also have been performed. Higher
plasma levels of ticagrelor and its active metabolite
with crushed tablets as compared with integral
tablets have been recently reported in healthy
subjects (4). Finally, unmeasured confounder and
overﬁtting risks cannot be excluded in our
multivariable model.
These limitations notwithstanding, the present
study provides unique and potentially important
insights in the treatment of STEMI patients.*Guido Parodi, MD, PhD
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Suppl 12:A229.TGFbR1 Inhibition Blocks
the Formation of Stenosis
in Tissue-Engineered
Vascular GraftsWe previously developed a tissue-engineered vas-
cular graft (TEVG), created by seeding a biodegrad-
able scaffold with autologous bone marrow–derived
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513mononuclear cells, speciﬁcally designed for use in
congenital heart surgery. We demonstrated in a clin-
ical trial that this approach is safe and effective
for short-term use in children with the added
beneﬁt of growth capacity; however, long-term re-
sults were complicated by the formation of TEVG
stenosis (1). Recently, it was shown that endothelial-
to-mesenchymal transition (EndoMT) contributes to
post-natal processes, including the development of
vein graft remodeling (2). Activation of transforming
growth factor-b (TGF-b) signaling is thought to play
a central role in this process (3,4). In this study, we
explore the contribution of EndoMT to vascular
neotissue and stenosis formation, and the potential
utility of anti–TGF-b therapy in the prevention of
TEVG stenosis.
We used endothelial cell lineage-tracing mouse
models (Tie2-Cre and Cdh5-CreERT2) to determine
whether EndoMT occurs during neovessel formation
in a mouse TEVG model. TEVG scaffolds were
constructed from a nonwoven polyglycolic acid
mesh, with a copolymer sealant solution of poly-L-
lactide and -ε-caprolactone, implanted as an inferior
vena cava interposition graft and harvested at the
2-week time point. In both models (n ¼ 9 and 7,
respectively), we found colocalization of both fate-
mapped endothelial cell (LacZ) and mesenchymal
cell (smooth muscle actin and Calponin) markers inFIGURE 1 TGFbR1 Inhibition Reduces TEVG Stenosis by Blocking End
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(A) Tie2 and Cdh5 models with lineage tracing images in occluded TEVG
that EndoMT signiﬁcantly contributes to TEVG stenosis in both models
lineage tracing model signiﬁcantly reduces the occurrence of EndoMT in
dimethyl sulfoxide; SMA ¼ smooth muscle actin.38% to 51% of smooth muscle cells in occluded
grafts and only 17% in patent grafts (Figure 1A)
(p < 0.05, p < 0.01), suggesting that excessive
EndoMT signiﬁcantly contributes to occlusion in
our TEVG.
Next, we evaluated the expression of TGF-b and
TGF-b receptor type 1 (TGFbR1) using our model sys-
tem with wild-type mice (C57BL/6) to determine their
association with the formation of TEVG stenosis.
Stenosed grafts expressed higher levels of TGF-b
compared with patent grafts and showed increased
expression of TGF-b and TGFbR1 by quantitative
real-time polymerase chain reaction from day 7 to
day 14 as stenosis developed (p < 0.001, n ¼ 5 for
each).
We then treated the mice (C57BL/6) with TGFbR1
inhibitor SB431542 at 10 mg/kg twice daily by
intraperitoneal administration for 2 weeks following
implantation of our TEVG (n ¼ 24). Matched
unseeded control and bone marrow–derived mono-
nuclear cell–seeded (1  106 cells/graft) mice
received intraperitoneal injection of sterile
dimethyl sulfoxide (n ¼ 25 each). At 8 weeks after
implantation, the grafts were evaluated with a
high-frequency Doppler ultrasound. The stenosis
rate was signiﬁcantly reduced in the TGFbR1 in-
hibitor group, similar to that of the seeded control
group (p < 0.05, p < 0.01), demonstrating theoMT
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. Arrows show co-localized cells (left). Quantiﬁcation demonstrating
(right, *p < 0.05, **p < 0.01). (B) SB431542 treatment in the Tie2
occluded TEVG. Arrows show co-localized cells (*p < 0.05). DMSO ¼
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514long-term efﬁcacy of the short-term SB431542
treatment.
To investigate the mechanism by which SB431542
treatment prevents TEVG stenosis, we treated mice
from the Tie2 lineage-tracing model (n ¼ 10) with
TGFbR1 inhibitor. Drug treatment reduced the oc-
currence of EndoMT, as demonstrated by signiﬁcant
reduction in the ratio of LacZ-positive smooth muscle
cells in occluded grafts in drug-treated mice
(Figure 1B) (p < 0.05). We then explored the use of
targeted drug delivery in an attempt to maximize
efﬁcacy and minimize the risk of any drug-related
adverse events, as well as to determine whether
local drug delivery could be used to mimic the
effects of cell seeding. We developed a poly-lactic
glycolic acid microparticle–based delivery system
allowing drug release directly from the graft (5).
The drug-eluting grafts were implanted in our
mouse model (C57BL/6) (n ¼ 10). We then compared
stenosis rates to unseeded grafts with empty
microparticles (n ¼ 10) and cell-seeded grafts
(n ¼ 25) at 2 weeks. These studies showed that
the best results were achieved with microparticle
drug delivery, which completely eliminated TEVG
stenosis, while also permitting vascular neotissue
formation.
In this study, we went from the bench to the
bedside and back in an attempt to design an improved
TEVG. Clinical investigation of our ﬁrst-generation
TEVG demonstrated that the TEVG possessed
growth capacity, but its clinical utility was limited by
a high incidence of stenosis. These ﬁndings prompted
us to investigate the cellular and molecular mecha-
nisms underlying vascular neotissue formation,
which lead us to discover that excessive EndoMT
contributes to neovessel stenosis in the TEVG. We
modulated EndoMT by administration of a TGFbR1
inhibitor and showed that TGFbR1 inhibition is a
viable strategy for preventing TEVG stenosis without
blocking neovessel formation. Finally, we demon-
strated that local-controlled release of the TGFbR1
inhibitor recapitulates the functional results achieved
using cell seeding. This drug-eluting scaffold will
serve as the prototype for our second-generation
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QRS Duration in Patients
Receiving Cardiac
Resynchronization TherapyZusterzeel et al. (1) reported in the September 2, 2014,
issue of the Journal on the predictive merits of QRS
morphology and QRS duration (QRSd) following
implementation of cardiac resynchronization therapy
(CRT), analyzing 31,892 patients from the National
